Resource Logo
Reuters New Media

Alnylam drug found effective in treating rare genetic disease




 

(Reuters) - Alnylam Pharmaceuticals Inc said an early-stage trial of its gene-based therapy showed the drug was effective in suppressing a protein that causes a rare organ-damaging hereditary disorder.

Alnylam shares rose 14 percent to $42.80 in premarket trade.

The study was testing a subcutaneously administered version of the drug, ALN-TTR, to treat genetic disorder amyloidosis, which is caused by deposits of protein in tissues and organs.

The therapy is based on Alnylam's gene silencing technology that works by "switching off" certain disease-causing genes and is widely believed to hold immense potential for treating diseases ranging from cancer to HIV.

(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)



 


Copyright © 2013 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in July 11, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.